申请人:James Black Foundation Limited
公开号:US06407132B1
公开(公告)日:2002-06-18
Compounds of formula (I) and their pharmaceutically acceptable salts are useful as histamine H3 receptor ligands. R1 and R3 are optional substituents such as C1 to C6 alkyl. R2 represents a bond or C1 to C5 (preferably C1 to C3) hydrocarbylene; R4 represents a bond or C1 to C5 (preferably C1 to C3) hydrocarbylene; R5 is hydrogen, C1 to C3 alkyl, R8—O—(C1 to C3)alkyl (wherein R8 is hydrogen or C1 to C3 alkyl), aryl, aryl(C1 to C3)alkyl; R6 represents a bond or —NR9—, wherein R9 is any of the groups mentioned above for R5; R7 is H or C1 to C15 hydrocarbyl (in which one or more hydrogen atoms may be replaced by halogen, and up to three carbon atoms may be replaced by oxygen, nitrogen or sulfur atoms); a is from 0 to 2; and b is from 0 to 3.
式(I)的化合物及其药学上可接受的盐可用作组胺H3受体配体。R1和R3是可选的取代基,如C1到C6烷基。R2代表键或C1到C5(优选C1到C3)的烃基; R4代表键或C1到C5(优选C1到C3)的烃基; R5是氢,C1到C3烷基,R8—O—(C1到C3)烷基(其中R8是氢或C1到C3烷基),芳基,芳基(C1到C3)烷基; R6代表键或—NR9—,其中R9是上述R5中提到的任何一种基团; R7是H或C1到C15的烃基(其中一个或多个氢原子可以被卤素取代,最多三个碳原子可以被氧、氮或硫原子取代); a为0到2; b为0到3。